296
Views
3
CrossRef citations to date
0
Altmetric
Original Article

Acute liver injury leading to death in the setting of brentuximab vedotin monotherapy

, &
Pages 2283-2286 | Received 08 Sep 2018, Accepted 28 Jan 2019, Published online: 01 Mar 2019

References

  • Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–2189.
  • Adcetris.com [Internet]. Seattle, Washington: Seattle Genetics. 2018 [cited 2018 Mar 14]. Available from: http://adcetris.com
  • Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16:888–897.
  • Gravanis I, Tzogani K, Hennik P, et al. The European medicines agency review of brentuximab vedotin (adcetris) for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma or systemic anaplastic large cell lymphoma: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2016;21:102–109.
  • Zhao B, Chen R, O’Connor OA, et al. Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment. Br J Clin Pharmacol. 2016;82:696–705.
  • Fanale M, Whiting N, Forero-Torres A, et al. Treatment strategies to optimise outcomes with Brentuximab vedotin: management of common and rare toxicities. J Targ Ther Ca. 2015;4:36–44.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.